Source: Annual Congress 2006 - Epidemiology and clinical aspects of tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Selcuk Sonmez, G. Dulkar, A. Ozcan (Ankara, Turkey). The problem of one drug resistance in tuberculosis. Eur Respir J 2006; 28: Suppl. 50, 4942

Member's Comments

No comment yet.

Related content which might interest you: The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001 Primary drug resistance against mycobacterium tuberculosis in a high burden country Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006 Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 The effects of drug resistance phenotype on proliferation of Mycobacterium tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006 The impact of drug resistance on TB control and elimination Source: International Congress 2014 – New diagnostics and better treatments for multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) Year: 2014 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Mefloquine as a potential drug against multidrug-resistant tuberculosis Source: Eur Respir J 2015; 46: 1503-1505 Year: 2015 The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis Source: Eur Respir J 2012; 39: 626-634 Year: 2012 Mycobacterium tuberculosis drug resistance surveillance in Belarus Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 The looming threat of bedaquiline resistance in tuberculosis Source: Eur Respir J, 55 (6) 2000718; 10.1183/13993003.00718-2020 Year: 2020 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007 The problem of multi-drug resistant (MDR)-TB Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008